Amdoxovir

Amdoxovir
Clinical data
ATC code
  • none
Identifiers
IUPAC name
  • [(2R,4R)-4-(2,6-diaminopurin-9-yl)-1,3-dioxolan-2-yl]methanol
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
NIAID ChemDB
Chemical and physical data
FormulaC9H12N6O3
Molar mass252.234 g·mol−1
3D model (JSmol)
SMILES
  • n2c1c(nc(nc1n(c2)[C@@H]3O[C@@H](OC3)CO)N)N
InChI
  • InChI=1S/C9H12N6O3/c10-7-6-8(14-9(11)13-7)15(3-12-6)4-2-17-5(1-16)18-4/h3-5,16H,1-2H2,(H4,10,11,13,14)/t4-,5-/m1/s1 checkY
  • Key:RLAHNGKRJJEIJL-RFZPGFLSSA-N checkY
  (verify)

Amdoxovir is a pharmaceutical drug that has undergone research for the treatment of HIV/AIDS. It acts as a nucleoside reverse transcriptase inhibitor (NRTI). The drug was discovered by Raymond F. Schinazi (Emory University) and C.K. Chu (University of Georgia) and developed by RFS Pharma.[1]

Amdoxovir was in advanced Phase II clinical trials around 2010.[2] In 2013, a Phase II trial was terminated[3] and another was withdrawn before it started.[4] No further studies appear to have been done.

References

  1. ↑ "Amdoxovir". AIDSmeds.com. January 13, 2009. Archived from the original on 2008-03-21. Retrieved March 21, 2008.
  2. ↑ Murphy RL, Kivel NM, Zala C, Ochoa C, Tharnish P, Mathew J, Pascual ML, Schinazi RF (2010). "Antiviral activity and tolerability of amdoxovir with zidovudine in a randomized double-blind placebo-controlled study in HIV-1-infected individuals". Antivir Ther. 15 (2): 185–192. doi:10.3851/IMP1514. PMC 7733239. PMID 20386073.
  3. ↑ Clinical trial number NCT01737359 for "A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects" at ClinicalTrials.gov
  4. ↑ Clinical trial number NCT01738555 for "A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects" at ClinicalTrials.gov
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.